StockFacets
About
Sign-up
Sign-in
Earnings Calendar
Prices are updated after-hours
Published
Previous years
186
This month
3
This week
1
This year
14
Publishing Date
2024 - 03 - 11
2
2024 - 03 - 10
2
2024 - 03 - 04
2
2024 - 01 - 16
2
2023 - 12 - 18
2
2023 - 10 - 13
4
2023 - 08 - 07
2
2023 - 03 - 21
2
2023 - 03 - 18
3
2023 - 03 - 15
2
2023 - 01 - 27
2
2022 - 10 - 04
2
2022 - 08 - 23
2
2022 - 06 - 07
5
2022 - 01 - 14
2
2021 - 11 - 30
2
2021 - 09 - 30
3
2021 - 09 - 27
2
2021 - 09 - 23
1
2021 - 09 - 21
3
2021 - 09 - 13
1
2021 - 09 - 09
1
2021 - 08 - 30
3
2021 - 08 - 24
1
2021 - 08 - 19
1
2021 - 08 - 16
1
2021 - 08 - 04
1
2021 - 07 - 16
2
2021 - 06 - 28
2
2021 - 06 - 25
1
2021 - 06 - 14
2
2021 - 06 - 13
1
2021 - 06 - 11
1
2021 - 06 - 08
1
2021 - 06 - 01
1
2021 - 05 - 25
1
2021 - 05 - 24
1
2021 - 05 - 03
1
2021 - 04 - 29
1
2021 - 04 - 23
4
2021 - 04 - 22
1
2021 - 04 - 20
1
2021 - 04 - 12
1
2021 - 04 - 07
3
2021 - 04 - 06
1
2021 - 04 - 02
1
2021 - 03 - 22
1
2021 - 03 - 15
1
2021 - 03 - 01
3
2021 - 02 - 23
1
2021 - 02 - 19
1
2021 - 01 - 20
1
2021 - 01 - 13
1
2021 - 01 - 11
1
2020 - 12 - 14
1
2020 - 12 - 10
2
2020 - 12 - 09
1
2020 - 12 - 02
1
2020 - 10 - 20
1
2020 - 07 - 07
1
Sector
Health technology
172
Manufacturing
7
Process industries
1
Professional, scientific, and technical services
8
Tags
Alliances
4
Als
4
Antibody
3
Application
5
Approval
10
Asia
3
Atopic dermatitis
83
Baricitinib
3
Biocapital
4
Biomidwest
4
Biopharma
8
Bioscience
4
Biotech-bay
4
Biotech-beach
3
Cbp-201
4
Children
23
China
6
Chmp
3
Clearance
4
Clinical-trials-phase-ii
11
Clinical-trials-phase-iii
12
Conference
4
Derm
4
Dermatitis
185
Disease
3
Drug
13
Dupixent
22
Enroll
6
Europe
5
Events
5
Fda
13
Fmx114
4
Lnk0100
5
Market
4
Meeting
5
N/a
111
New drug
6
Opzelura
3
Pharmaceuticals
14
Phase 1
7
Phase 1b
10
Phase 2
13
Phase 2b
23
Phase 3
14
Positive
29
Potential
8
Presentation
4
Product-news
4
Program
5
Regulatory
4
Research
5
Results
22
Six
5
Skin
8
Study
15
Therapeutics
20
Topline
15
Treatment
38
Trial
69
Trials
7
Entities
Abbvie inc.
13
Aclaris therapeutics, inc.
6
Aldeyra therapeutics, inc.
2
Allakos inc.
2
Amgen inc.
3
Anaptysbio, inc.
2
Apogee therapeutics, inc.
2
Arcutis biotherapeutics, inc.
16
Arrival
1
Aslan pharmaceuticals limited
22
Astellas pharma inc
2
Astrazeneca plc
1
Bausch health companies inc.
3
Beigene, ltd.
2
Bellus health inc.
2
Biomx inc.
3
Bristol-myers squibb company
2
Cara therapeutics, inc.
3
Castle biosciences, inc.
1
Connect biopharma holdings ltd - adr
8
Corvus pharmaceuticals, inc.
1
Dermtech, inc.
1
Elanco animal health incorporated
1
Eli lilly and company
18
Evelo biosciences, inc.
4
Glaxosmithkline plc
1
Hoth therapeutics, inc.
9
Incyte corporation
11
Johnson & johnson
6
Kymera therapeutics, inc.
1
Nektar therapeutics
3
Novartis ag
3
Pfizer, inc.
6
Phibro animal health corporation
1
Rapt therapeutics, inc.
6
Regeneron pharmaceuticals, inc.
17
Roivant sciences ltd.
4
Sanofi
36
Teva pharmaceutical industries ltd
7
Thermo fisher scientific inc
1
Viatris inc.
2
Vyne therapeutics inc.
6
Zoetis inc.
1
Symbols
ABBV
13
ACRS
6
ALDX
2
ALLK
2
ALPMF
2
ALPMY
2
AMGN
3
ANAB
2
APGE
2
ARQT
16
ARVL
1
ASLN
22
AZN
1
AZNCF
1
BGNE
2
BHC
3
BLU
2
BMY
2
CARA
3
CNTB
8
CRVS
1
CSTL
1
DMTK
1
ELAN
1
EVLO
4
GSK
1
HOTH
9
INCY
11
JNJ
6
KYMR
1
LLY
18
NKTR
3
NVS
3
NVSEF
2
PAHC
1
PFE
6
PHGE
3
RAPT
6
REGN
17
ROIV
4
SNY
36
SNYNF
26
TEVJF
7
TMO
1
VTRS
2
VYNE
6
ZTS
1
Exchanges
Amex
3
Nasdaq
152
Nyse
44
Crawled Date
2024 - 03 - 11
2
2024 - 03 - 10
2
2024 - 03 - 04
2
2024 - 01 - 16
2
2023 - 12 - 18
2
2023 - 10 - 13
4
2023 - 08 - 07
2
2023 - 03 - 21
2
2023 - 03 - 18
3
2023 - 03 - 15
2
2023 - 01 - 27
2
2022 - 10 - 04
2
2022 - 08 - 23
2
2022 - 06 - 07
5
2022 - 01 - 14
2
2021 - 11 - 30
2
2021 - 09 - 30
3
2021 - 09 - 27
2
2021 - 09 - 23
1
2021 - 09 - 22
1
2021 - 09 - 21
2
2021 - 09 - 13
1
2021 - 09 - 09
1
2021 - 08 - 30
3
2021 - 08 - 24
1
2021 - 08 - 19
1
2021 - 08 - 16
1
2021 - 08 - 04
1
2021 - 07 - 16
2
2021 - 06 - 28
2
2021 - 06 - 25
1
2021 - 06 - 14
2
2021 - 06 - 13
1
2021 - 06 - 11
1
2021 - 06 - 08
1
2021 - 06 - 01
1
2021 - 05 - 25
1
2021 - 05 - 24
1
2021 - 05 - 03
1
2021 - 04 - 29
1
2021 - 04 - 23
4
2021 - 04 - 22
1
2021 - 04 - 20
1
2021 - 04 - 12
1
2021 - 04 - 07
3
2021 - 04 - 06
1
2021 - 04 - 02
1
2021 - 03 - 22
1
2021 - 03 - 15
1
2021 - 03 - 01
3
2021 - 02 - 23
1
2021 - 02 - 19
1
2021 - 01 - 20
1
2021 - 01 - 13
1
2021 - 01 - 11
1
2020 - 12 - 16
2
2020 - 12 - 14
1
2020 - 12 - 10
2
2020 - 12 - 09
1
2020 - 12 - 02
1
Crawled Time
00:00
2
01:00
1
05:00
5
06:00
4
07:00
5
08:00
4
09:00
1
11:00
19
11:03
1
12:00
30
12:01
1
12:04
1
12:20
7
12:30
2
13:00
16
13:03
1
13:15
1
13:20
2
13:30
2
14:00
15
14:01
1
14:12
1
14:15
2
14:20
2
14:30
1
15:00
7
15:30
2
15:56
2
16:00
4
16:20
3
17:00
5
18:00
7
19:00
4
20:00
3
20:20
3
21:00
8
22:00
5
23:00
6
Source
arcutis.com
4
aslanpharma.com
1
ir.hoththerapeutics.com
3
www.anaptysbio.com
2
www.aslanpharma.com
3
www.biospace.com
74
www.evelobio.com
1
www.globenewswire.com
63
www.ppdi.com
1
www.prnewswire.com
32
www.vynetherapeutics.com
2
Sort by:
after hours % change
|
delayed % change
|
gain open
|
gain high
|
gain close
|
publishing date
(GMT-12:00) International Date Line West
(GMT-11:00) American Samoa
(GMT-11:00) Midway Island
(GMT-10:00) Hawaii
(GMT-09:00) Alaska
(GMT-08:00) Pacific Time (US & Canada)
(GMT-08:00) Tijuana
(GMT-07:00) Arizona
(GMT-07:00) Chihuahua
(GMT-07:00) Mazatlan
(GMT-07:00) Mountain Time (US & Canada)
(GMT-06:00) Central America
(GMT-06:00) Central Time (US & Canada)
(GMT-06:00) Guadalajara
(GMT-06:00) Mexico City
(GMT-06:00) Monterrey
(GMT-06:00) Saskatchewan
(GMT-05:00) Bogota
(GMT-05:00) Eastern Time (US & Canada)
(GMT-05:00) Indiana (East)
(GMT-05:00) Lima
(GMT-05:00) Quito
(GMT-04:00) Atlantic Time (Canada)
(GMT-04:00) Caracas
(GMT-04:00) Georgetown
(GMT-04:00) La Paz
(GMT-04:00) Puerto Rico
(GMT-04:00) Santiago
(GMT-03:30) Newfoundland
(GMT-03:00) Brasilia
(GMT-03:00) Buenos Aires
(GMT-03:00) Greenland
(GMT-03:00) Montevideo
(GMT-02:00) Mid-Atlantic
(GMT-01:00) Azores
(GMT-01:00) Cape Verde Is.
(GMT+00:00) Casablanca
(GMT+00:00) Dublin
(GMT+00:00) Edinburgh
(GMT+00:00) Lisbon
(GMT+00:00) London
(GMT+00:00) Monrovia
(GMT+00:00) UTC
(GMT+01:00) Amsterdam
(GMT+01:00) Belgrade
(GMT+01:00) Berlin
(GMT+01:00) Bern
(GMT+01:00) Bratislava
(GMT+01:00) Brussels
(GMT+01:00) Budapest
(GMT+01:00) Copenhagen
(GMT+01:00) Ljubljana
(GMT+01:00) Madrid
(GMT+01:00) Paris
(GMT+01:00) Prague
(GMT+01:00) Rome
(GMT+01:00) Sarajevo
(GMT+01:00) Skopje
(GMT+01:00) Stockholm
(GMT+01:00) Vienna
(GMT+01:00) Warsaw
(GMT+01:00) West Central Africa
(GMT+01:00) Zagreb
(GMT+01:00) Zurich
(GMT+02:00) Athens
(GMT+02:00) Bucharest
(GMT+02:00) Cairo
(GMT+02:00) Harare
(GMT+02:00) Helsinki
(GMT+02:00) Jerusalem
(GMT+02:00) Kaliningrad
(GMT+02:00) Kyiv
(GMT+02:00) Pretoria
(GMT+02:00) Riga
(GMT+02:00) Sofia
(GMT+02:00) Tallinn
(GMT+02:00) Vilnius
(GMT+03:00) Baghdad
(GMT+03:00) Istanbul
(GMT+03:00) Kuwait
(GMT+03:00) Minsk
(GMT+03:00) Moscow
(GMT+03:00) Nairobi
(GMT+03:00) Riyadh
(GMT+03:00) St. Petersburg
(GMT+03:30) Tehran
(GMT+04:00) Abu Dhabi
(GMT+04:00) Baku
(GMT+04:00) Muscat
(GMT+04:00) Samara
(GMT+04:00) Tbilisi
(GMT+04:00) Volgograd
(GMT+04:00) Yerevan
(GMT+04:30) Kabul
(GMT+05:00) Ekaterinburg
(GMT+05:00) Islamabad
(GMT+05:00) Karachi
(GMT+05:00) Tashkent
(GMT+05:30) Chennai
(GMT+05:30) Kolkata
(GMT+05:30) Mumbai
(GMT+05:30) New Delhi
(GMT+05:30) Sri Jayawardenepura
(GMT+05:45) Kathmandu
(GMT+06:00) Almaty
(GMT+06:00) Astana
(GMT+06:00) Dhaka
(GMT+06:00) Urumqi
(GMT+06:30) Rangoon
(GMT+07:00) Bangkok
(GMT+07:00) Hanoi
(GMT+07:00) Jakarta
(GMT+07:00) Krasnoyarsk
(GMT+07:00) Novosibirsk
(GMT+08:00) Beijing
(GMT+08:00) Chongqing
(GMT+08:00) Hong Kong
(GMT+08:00) Irkutsk
(GMT+08:00) Kuala Lumpur
(GMT+08:00) Perth
(GMT+08:00) Singapore
(GMT+08:00) Taipei
(GMT+08:00) Ulaanbaatar
(GMT+09:00) Osaka
(GMT+09:00) Sapporo
(GMT+09:00) Seoul
(GMT+09:00) Tokyo
(GMT+09:00) Yakutsk
(GMT+09:30) Adelaide
(GMT+09:30) Darwin
(GMT+10:00) Brisbane
(GMT+10:00) Canberra
(GMT+10:00) Guam
(GMT+10:00) Hobart
(GMT+10:00) Melbourne
(GMT+10:00) Port Moresby
(GMT+10:00) Sydney
(GMT+10:00) Vladivostok
(GMT+11:00) Magadan
(GMT+11:00) New Caledonia
(GMT+11:00) Solomon Is.
(GMT+11:00) Srednekolymsk
(GMT+12:00) Auckland
(GMT+12:00) Fiji
(GMT+12:00) Kamchatka
(GMT+12:00) Marshall Is.
(GMT+12:00) Wellington
(GMT+12:45) Chatham Is.
(GMT+13:00) Nuku'alofa
(GMT+13:00) Samoa
(GMT+13:00) Tokelau Is.
atopic dermatitis
published :
Previous years
save search
ASLAN Pharmaceuticals Announces Positive Interim Results From Phase 2 Study of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients
Published:
2024-04-22
(Crawled : 13:00)
- globenewswire.com
ASLN
|
News
|
$0.4863
3.69%
3.56%
1M
|
Health Technology
|
-7.84%
|
O:
13.73%
H:
5.17%
C:
-20.69%
dermatitis
positive
pharmaceuticals
results
study
Corvus Pharmaceuticals Announces Initiation of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
Published:
2024-04-09
(Crawled : 20:00)
- globenewswire.com
CRVS
|
$1.58
3.27%
3.16%
91K
|
Health Technology
|
-7.36%
|
O:
2.45%
H:
0.0%
C:
-9.58%
dermatitis
pharmaceuticals
for
trial
Eczema Therapeutics Market size is set to grow by USD 5.81 bn from 2024-2028,high prevalence of atopic dermatitis boost the market- Technavio
Published:
2024-04-08
(Crawled : 18:00)
- prnewswire.com
SNYNF
|
News
|
$94.25
-2.18%
480
|
Health Technology
|
1.41%
|
O:
2.24%
H:
0.0%
C:
-0.8%
AZNCF
|
News
|
$140.3
-4.19%
1.5K
|
Health Technology
|
1.6%
|
O:
-3.43%
H:
6.21%
C:
6.21%
VTRS
|
News
A
|
$11.55
1.67%
1.65%
7.2M
|
Health Technology
|
-2.12%
|
O:
-0.25%
H:
1.1%
C:
-0.17%
NVS
|
News
|
$98.35
1.1%
0.0%
2.2M
|
Health Technology
|
2.67%
|
O:
-0.05%
H:
0.43%
C:
-0.27%
BMY
|
$48.86
-0.27%
-0.02%
16M
|
Health Technology
|
-4.79%
|
O:
-0.08%
H:
0.04%
C:
-0.35%
BHC
|
$8.56
0.35%
0.0%
2M
|
Health Technology
|
-17.77%
|
O:
0.38%
H:
0.0%
C:
-7.27%
ABBV
|
News
|
$167.8
-1.03%
-0.06%
4.1M
|
Health Technology
|
-0.07%
|
O:
0.77%
H:
1.63%
C:
0.35%
SNY
|
News
|
$46.66
-2.16%
-2.21%
1.7M
|
Health Technology
|
1.11%
|
O:
0.84%
H:
0.0%
C:
0.0%
AZN
|
News
|
$71.175
0.46%
0.46%
6.1M
|
Health Technology
|
5.56%
|
O:
0.18%
H:
0.3%
C:
0.19%
eczema
dermatitis
set
therapeutics
market
Lynk Pharmaceuticals Announces First Atopic Dermatitis Patient Dosed in Phase Ⅲ Clinical Study of LNK01001
Published:
2024-03-22
(Crawled : 12:00)
- prnewswire.com
JNJ
|
News
|
$148.53
-0.69%
-0.14%
9.6M
|
Health Technology
|
-4.75%
|
O:
0.02%
H:
0.0%
C:
0.0%
lnk0100
first
dermatitis
pharmaceuticals
study
ASLAN Pharmaceuticals Provides TREK-DX Study Update and Highlights Potential of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients
Published:
2024-03-11
(Crawled : 11:00)
- globenewswire.com
ASLN
|
News
|
$0.4863
3.69%
3.56%
1M
|
Health Technology
|
-24.8%
|
O:
0.16%
H:
203.51%
C:
160.38%
dermatitis
update
pharmaceuticals
potential
study
Press Release: New Phase 2b results for amlitelimab support potential for best-in-class maintenance of response in atopic dermatitis
Published:
2024-03-11
(Crawled : 06:00)
- globenewswire.com
SNY
|
News
|
$46.66
-2.16%
-2.21%
1.7M
|
Health Technology
|
-1.28%
|
O:
0.57%
H:
0.0%
C:
0.0%
dermatitis
response
potential
results
More than two-thirds of people with atopic dermatitis and skin of color experienced skin improvement in a first-of-its-kind lebrikizumab study
Published:
2024-03-10
(Crawled : 20:20)
- prnewswire.com
LLY
|
News
|
$732.2
-1.81%
0.18%
2.1M
|
Health Technology
|
-1.3%
|
O:
-1.3%
H:
0.61%
C:
-2.37%
dermatitis
skin
study
Arcutis Presents Late-Breaking Data From INTEGUMENT-PED Phase 3 Trial of Roflumilast Cream 0.05% in Atopic Dermatitis in Children Ages 2 to 5 at the American Academy of Dermatology Annual Meeting
Published:
2024-03-10
(Crawled : 20:20)
- globenewswire.com
ARQT
|
$8.76
0.23%
0.23%
2M
|
Health Technology
|
-21.52%
|
O:
0.18%
H:
3.39%
C:
-10.12%
children
dermatitis
meeting
trial
Apogee to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trial for APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases on March 5, 2024
Published:
2024-03-04
(Crawled : 21:00)
- globenewswire.com
APGE
|
$46.58
-6.41%
-6.85%
260K
|
|
11.5%
|
O:
43.53%
H:
9.18%
C:
-1.02%
apg777
conference
report
antibody
dermatitis
treatment
trial
results
Arcutis Announces Acceptance of Late Breaking Abstract in Atopic Dermatitis Among Five New Topical Roflumilast Data Being Presented at the American Academy of Dermatology Annual Meeting
Published:
2024-03-04
(Crawled : 14:00)
- arcutis.com
ARQT
|
$8.76
0.23%
0.23%
2M
|
Health Technology
|
-25.66%
|
O:
2.29%
H:
2.57%
C:
-9.05%
dermatitis
meeting
Allakos Announces Phase 2 Lirentelimab Trials in Atopic Dermatitis and Chronic Spontaneous Urticaria Did Not Meet Their Primary Endpoints
Published:
2024-01-16
(Crawled : 12:00)
- globenewswire.com
ALLK
|
$1.03
-1.91%
-1.94%
250K
|
Health Technology
|
-65.89%
|
O:
-59.2%
H:
10.66%
C:
-2.46%
urticaria
dermatitis
trials
Dupixent® (dupilumab) U.S. Label Updated with Data Further Supporting Use in Atopic Dermatitis with Moderate-to-Severe Hand and Foot Involvement
Published:
2024-01-16
(Crawled : 12:00)
- globenewswire.com
SNYNF
|
News
|
$94.25
-2.18%
480
|
Health Technology
|
-11.32%
|
O:
-2.03%
H:
0.05%
C:
0.05%
SNY
|
News
|
$46.66
-2.16%
-2.21%
1.7M
|
Health Technology
|
-9.4%
|
O:
-1.34%
H:
0.0%
C:
0.0%
REGN
|
News
|
$906.55
-0.09%
-0.08%
370K
|
Health Technology
|
-2.86%
|
O:
-0.21%
H:
0.67%
C:
0.66%
dupixent
label
dermatitis
Majority of Individuals with Atopic Dermatitis Improved with Arcutis’ Roflumilast Cream 0.15% According to New Data from Phase 3 Program
Published:
2024-01-14
(Crawled : 12:20)
- arcutis.com
ARQT
|
$8.76
0.23%
0.23%
2M
|
Health Technology
|
Email alert
Add to watchlist
dermatitis
program
Aclaris Therapeutics Announces Top-line Results from 4-Week Phase 2b Trial of ATI-1777 for Mild to Severe Atopic Dermatitis
Published:
2024-01-10
(Crawled : 12:00)
- globenewswire.com
ACRS
|
$1.185
-2.87%
-2.95%
1.3M
|
Health Technology
|
-8.59%
|
O:
-16.41%
H:
6.54%
C:
-6.07%
ati-1777
dermatitis
trial
therapeutics
results
Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from Phase 2 Clinical Trial of ADX-629 in Patients with Atopic Dermatitis
Published:
2023-12-18
(Crawled : 23:00)
- biospace.com/
ALDX
|
$3.93
0.51%
0.51%
570K
|
Health Technology
|
30.46%
|
O:
1.32%
H:
3.27%
C:
-3.27%
adx-629
conference
dermatitis
trial
therapeutics
results
Cara Therapeutics Announces Outcome from Dose-Finding Part A of KIND 1 Study Evaluating Oral Difelikefalin for Moderate-to-Severe Pruritus in Patients with Atopic Dermatitis
Published:
2023-12-18
(Crawled : 12:00)
- globenewswire.com
CARA
|
$0.6777
-4.16%
-4.34%
220K
|
Health Technology
|
-45.53%
|
O:
-4.88%
H:
0.0%
C:
-46.23%
pruritus
dermatitis
therapeutics
study
Kymera Therapeutics Announces First Patient Dosed in Phase 2 Atopic Dermatitis Clinical Trial of KT-474 (SAR444656), a First-in-Class, Investigational IRAK4 Degrader, Generating a $15 Million Payment from Sanofi
Published:
2023-12-07
(Crawled : 12:00)
- globenewswire.com
SNYNF
|
News
|
$94.25
-2.18%
480
|
Health Technology
|
2.05%
|
O:
-1.66%
H:
0.0%
C:
0.0%
SNY
|
News
|
$46.66
-2.16%
-2.21%
1.7M
|
Health Technology
|
2.54%
|
O:
-1.19%
H:
0.0%
C:
0.0%
KYMR
|
$35.18
-1.48%
-1.51%
380K
|
Health Technology
|
59.39%
|
O:
-0.41%
H:
8.09%
C:
7.64%
kt-474
first
dermatitis
payment
trial
therapeutics
sanofi
FDA Accepts Arcutis’ Supplemental New Drug Application for Roflumilast Cream 0.15% for the Treatment of Atopic Dermatitis in Adults and Children Down to Age 6
Published:
2023-11-29
(Crawled : 13:00)
- globenewswire.com
ARQT
|
$8.76
0.23%
0.23%
2M
|
Health Technology
|
328.92%
|
O:
0.49%
H:
9.76%
C:
-7.32%
fda
drug
children
dermatitis
treatment
application
RAPT Therapeutics Announces Publication of Phase 1a/1b Clinical Trial of Zelnecirnon (RPT193) to Treat Atopic Dermatitis in Allergy
Published:
2023-11-27
(Crawled : 13:00)
- globenewswire.com
RAPT
|
$7.905
-1.19%
-1.2%
290K
|
Health Technology
|
-43.08%
|
O:
-1.22%
H:
2.12%
C:
0.88%
rpt193
dermatitis
publication
treat
trial
therapeutics
Connect Biopharma Announces Positive Long-Term Data from the China Pivotal Trial of Rademikibart in Patients with Moderate-to-Severe Atopic Dermatitis
Published:
2023-11-21
(Crawled : 11:00)
- globenewswire.com
CNTB
|
$1.39
3.57%
41K
|
Professional, Scientific, and T...
|
-33.5%
|
O:
6.31%
H:
2.28%
C:
-42.47%
dermatitis
positive
biopharma
trial
china
← Previous
1
2
3
4
5
6
7
8
9
10
Next →
Gainers vs Losers
62%
38%
Top 10 Gainers
CSSE
4
|
$0.4323
183.85%
64.77%
220M
|
Consumer Services
BOF
|
$1.99
70.09%
41.21%
110M
|
ILAG
|
$0.51
6.03%
40.62%
1.7M
|
LICN
|
$0.941
68.04%
40.49%
15M
|
AMST
|
$3.31
65.5%
39.58%
70M
|
Technology Services
MTC
|
$3.615
61.38%
38.04%
9.3M
|
Technology Services
WIMI
|
$1.15
58.53%
36.92%
19M
|
Technology Services
AIH
|
$0.45
12.5%
30.92%
320K
|
Health Services
MULN
|
News
|
$3.78
38.46%
27.78%
13M
|
Information
RILY
|
$29.86
37.48%
27.26%
12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.